Trials / Completed
CompletedNCT00163215
Growth Retardation In Children With Special Pathological Conditions Or Disease
Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 11 Years – 13 Years
- Healthy volunteers
- Not accepted
Summary
To show an increase in annual growth rate 3 years after Visit 2. Annual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of GH treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin | Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2005-09-13
- Last updated
- 2012-12-19
- Results posted
- 2012-12-19
Locations
18 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00163215. Inclusion in this directory is not an endorsement.